Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
American Journal of Clinical Dermatology
Erschienen in: American Journal of Clinical Dermatology 9/2002

01.12.2002 | Current Opinion

Oral Antivirals Revisited in the Treatment of Herpes Zoster

What Do They Accomplish?

verfasst von: Dr Arjen F. Nikkels, Gérald E. Piérard

Erschienen in: American Journal of Clinical Dermatology | Ausgabe 9/2002

Einloggen, um Zugang zu erhalten

Abstract

Oral antiviral agents currently represent the most important therapeutic keystone in the treatment of herpes zoster. Three oral antiviral agents are available for the treatment of herpes zoster: acyclovir, its derivative valacyclovir, and famciclovir. Meta-analysis of published data has shown that oral acyclovir significantly reduces various herpes zoster-related symptoms as well as the duration, intensity and prevalence of zoster-associated pain (ZAP). However, this drug does not influence postherpetic neuralgia. The newer agents famciclovir and valacyclovir exhibit a better oral bioavailability than acyclovir. These agents have demonstrated similar efficacy to acyclovir with ZAP and they require less frequent administration.
When initiated within 72 hours, oral antiviral therapy of herpes zoster is beneficial in selected, elderly immunocompetent patients, reducing the duration and intensity of ZAP and providing more rapid skin lesion healing. Oral antivirals are also of benefit in immunocompromised patients with uncomplicated herpes zoster. However, signs of cutaneous and visceral dissemination should be monitored; if signs occur, intravenous antiviral therapy is indicated.
Literatur
1.
Grose C. Varicella zoster virus infections: chickenpox, shingles, and varicella vaccine. In: Glaser R., Jones J.F., editors. Herpes virus infection. New York: Marcel Dekker Inc, 1994: 1117–85
2.
Arvin A.M. Varicella zoster virus. In: Fields B.N., Knipe D.M., Howley P.M., et al., editors. Fields virology. 3rd ed. Philadelphia (PA): Lippincott-Publishers, 1996: 2547–85
3.
Sanders H.W.A. Herpes zoster in de huisartspraktijk [doctoral thesis]. Nijmegen: University of Nijmegen, 1968
4.
Dworkin R.H., Perkins F.M., Nagasako E.M. Prospects for the prevention of postherpetic neuralgia in herpes zoster patients. Clin J Pain 2000; 16 (2 Suppl.): S90–100PubMedCrossRef
5.
Levin M.J. Vaccination against zoster. Pain Res Clin Manag 2001; 11: 131–42
6.
Petursson G., Helgason S., Gudmundsson S., et al. Herpes zoster in children and adolescents. Pediatr Infect Dis J 1998; 17: 905–8PubMedCrossRef
7.
Latif R., Shope T.C. Herpes zoster in normal and immunocompromised children. Am J Dis Child 1983; 137: 801–2PubMed
8.
Terada K., Kawano S., Yoshihiro K., et al. Characteristics of herpes zoster in otherwise normal children. Pediatr Infect Dis J 1993; 12: 960–1PubMedCrossRef
9.
Kakourou T., Theodoridou M., Mostrou G., et al. Herpes zoster in children. J Am Acad Dermatol 1998; 39: 207–10PubMedCrossRef
10.
Harding S.P., Porter S.M. Oral aciclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10: 177–82PubMedCrossRef
11.
Cobo M.L., Foulks G.N., Liesegang T.J., et al. Oral aciclovir in the therapy of acute herpes zoster ophthalmicus. Ophthalmology 1985; 92: 1574–83PubMed
12.
Cobo M. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir. Am J Med 1988; 85 Suppl. 2a: 90–3PubMed
13.
Borruat F.X., Buechi E.R., Piquet B., et al. Prevention des complications oculaires de l’herpes zoster ophthalmique par un traitement adequat d’acyclovir. Klin Monatsbl Augenheilkd 1991; 198: 358–60PubMedCrossRef
14.
Herbort C.P., Buechi E.R., Piquet B., et al. High-dose oral acyclovir in acute herpes zoster ophthalmicus: the end of the corticosteroid era. Curr Eye Res 1991; 10: 171–5PubMedCrossRef
15.
Colin J., Prisant O., Cochener B., et al. Comparison of the efficacy and safety of valaciclovir and acyclovir for the treatment of herpes zoster ophthalmicus. Ophthalmology 2000; 107: 1507–11PubMedCrossRef
16.
Balfour Jr H.H. Varicella-zoster virus infections in the immunocompromised host: natural history and treatment. Scand J Infect Dis 1991; 23 Suppl. 80: 69–74
17.
Balfour H.H. Varicella zoster infections in immunocompromised hosts. Am J Med 1988; 85 Suppl. 2A: 68–73PubMed
18.
Mandal B.K. Herpes zoster and the immunocompromised. J Infect 1987; 14: 15–9CrossRef
19.
Nikkels A.F., Delvenne P., Sadzot-Delvaux C., et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol 1996; 49: 243–8PubMedCrossRef
20.
Han C.S., Miller W., Haake R., et al. Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications. Bone Marrow Transplant 1994; 13: 277–83PubMed
21.
Nikkels A.F., Snoeck R., Rentier B., et al. Chronic verrucous varicella zoster virus skin lesions: clinical, histological, molecular and therapeutic aspects. Clin Exp Dermatol 1999; 24: 346–53PubMedCrossRef
22.
23.
O’Brien J.J., Campoli-Richards D.M. Acyclovir: an updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1989; 37: 233–309PubMedCrossRef
24.
Wagstaff A.J., Faulds D., Goa K.J. Aciclovir: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153–205PubMedCrossRef
25.
Perry C.M., Faulds D. Valaciclovir: a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in herpes virus infections. Drugs 1996; 52: 754–72PubMedCrossRef
26.
Ormrod D., Goa K. Valaciclovir: a review of its use in the management of herpes zoster. Drugs 2000; 59: 1317–40PubMedCrossRef
27.
Piérard G.E., Nikkels A.F. Le médicament du mois: le valaciclovir (Zelitrex). Rev Med Liege 1997; 52: 553–5PubMed
28.
Nikkels A.F., Piérard G.E. Comment je traite: le zona. Rev Med Liege 1999; 54: 71–5PubMed
29.
Nikkels A.F., Piérard G.E. Current therapies for shingles. Exp Opin Invest Drugs 1996; 5: 185–96CrossRef
30.
Perry C.M., Wagstaff A.J. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in herpes virus infections. Drugs 1995; 50: 396–415PubMedCrossRef
31.
Dworkin R.H., Carrington D., Cunningham A., et al. Assessment of pain in herpes zoster: lessons learned from antiviral trials. Antiviral Res 1997; 33: 73–85PubMedCrossRef
32.
Anonymous. A blue print for studies in herpes zoster. Expert Opin Herpes 1994; 7: 1–3
33.
Wood M.J., Balfour H., Beutner K., et al. How should zoster trials be conducted? J Antimicrob Chemother 1995; 36: 1089–101PubMedCrossRef
34.
Tyring S., Barbarash R.A., Nahlik J.E., et al. Collaborative famciclovir herpes zoster study group: famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995; 123: 89–96PubMed
35.
Kalman C.M., Laksin O.L. Herpes zoster and zosteriform herpes simplex virus infections in immunocompetent patients. Am J Med 1986; 81: 775–8PubMedCrossRef
36.
Bowsher D. The lifetime occurrence of herpes zoster and prevalence of postherpetic neuralgia: a retrospective study in an elderly population. Eur J Pain 1999; 3: 335–42PubMedCrossRef
37.
Burgoon C.F., Burgoon J.S., Baldridge G.D. The natural history of herpes zoster. JAMA 1957; 164: 265–9CrossRef
38.
Söltz-Szöts J. Kritische Bemerkungen sur Klinik und Therapie des Herpes Zoster. Zentralbl Haut u Geschlechtskrankheiten 1965; 38: 123–7
39.
Helgason S., Petursson G., Gudmundsson S., et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with a long term follow up. BMJ 2000; 321: 794–6PubMedCrossRef
40.
Helgason S., Sigurdsson J.A., Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12–6CrossRef
41.
De Moragas J.M., Kierland R.R. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193–6CrossRef
42.
Wood M.J., Ogan P.H., McKendrick M.W., et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85: 79–83PubMed
43.
Morton P., Thomson A.N. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93–5PubMed
44.
Beutner K.R., Friedman D.J., Forszpaniak C., et al. Valaciclovir compared with aciclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546–53PubMedCrossRef
45.
Wood M.J., Johnson R.W., McKendrick M.W., et al. A randomized trial of aciclovir for 7 days or 21 days with and without prednisolone for the treatment of acute herpes zoster. N Engl J Med 1994; 330: 896–900PubMedCrossRef
46.
Huff J.C., Bean B., Balfour H.H., et al. Therapy of herpes zoster with oral aciclovir. Am J Med 1988; 85: 84–9PubMedCrossRef
47.
Wassilew S.W., Reimlinger S., Nasemann T., et al. Oral acyclovir for herpes zoster: a double-blind controlled trial in normal subjects. Br J Dermatol 1987; 117: 495–501PubMedCrossRef
48.
Hoang-Xuan T., Buchi E.B., Herbort C.P., et al. Oral aciclovir for herpes zoster ophthalmicus. Ophthalmology 1992; 99: 1062–71PubMed
49.
Whithley R.J., Weiss H., Gnann J.W., et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 376–83
50.
Vander Straten M., Carrasco D., Lee P., et al. Reduction of postherpetic neuralgia in herpes zoster. J Cutan Med Surg 2001; 5: 409–16CrossRef
51.
Crooks R.J., Jones D.A., Fiddian A.P. Zoster-associated chronic pain: an overview of clinical trials with aciclovir. Scand J Infect Dis 1991; 23 Suppl. 78: 62–8
52.
Wood M.J., Kay R., Dworkin R.H., et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341–7PubMedCrossRef
53.
McKendrick M.W., Care C., Borke C., et al. Oral aciclovir in herpes zoster. J Antimicrob Chemother 1984; 14: 661–5PubMedCrossRef
54.
McKendrick M.W., McGill J.I., Wood M.J. Lack of effect of acyclovir on postherpetic neuralgia. BMJ 1989; 298: 431PubMedCrossRef
55.
Degreef H., and the Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241–6PubMedCrossRef
56.
Anonymous. Famciclovir safe and effective for management of shingles. AIDS Patient Care STDS 1997; 11: 198
57.
Tyring S., Belanger R., Bezwoda W., et al. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001; 19: 13–22PubMedCrossRef
58.
Tyring S., Engst R., Corriveau C., et al. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. Br J Ophthalmol 2001; 85: 576–81PubMedCrossRef
59.
Eaglestein W.H., Katz R., Brown J.A. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211: 1681–3CrossRef
60.
Esmann V., Geil J.P., Kroon S., et al. Prednisolone does not prevent postherpetic neuralgia. Lancet 1987; II: 126–9CrossRef
61.
Dworkin R.H., Boon R.J., Griffin D.R.G., et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998; 178 Suppl. 1: 71–5CrossRef
62.
Whitley R.J., Gnann J.W. Herpes zoster: focus on treatment in older adults. Antiviral Res 1999; 44: 145–54PubMedCrossRef
63.
Whitley R.J., Gnann Jr J.W., Weiss H.L., et al. Unique clinical trial design: combination acyclovir plus prednisone therapy of localized zoster in the normal host. Antiviral Res 1996; 29: 67–8PubMedCrossRef
64.
Tyring S.K., Beutner K.R., Tucker B.A., et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valaciclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–9PubMedCrossRef
65.
Choo P.W., Galil K., Donahue J.G., et al. Risk factors for postherpetic neuralgia. Arch Intern Med 1997; 157: 1217–24PubMedCrossRef
66.
Alper B.S., Lewis P.R. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255–64PubMed
67.
Johnson R. Herpes zoster-predicting and minimizing the impact of post-herpetic neuralgia. J Antimicrob Chemother 2001; 47 Suppl. 1: 1–8PubMedCrossRef
68.
Wacker P., Hartmann O., Benhamou E., et al. Varicella zoster virus infections after autologous bone marrow transplantation in children. Bone Marrow Transplant 1989; 4: 191–4PubMed
69.
Perren R.J., Powles R.L., Easton D., et al. Prevention of herpes zoster in patients by long term oral acyclovir after allogenic bone marrow transplantation. Am J Med 1988; 85 Suppl. 2A: 99–101PubMed
70.
Van Den Broek P.J., Van Der Meer J.W., Mulder J.D., et al. Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo controlled study. Infection 1984; 12: 338–41PubMedCrossRef
71.
Marshall T. Postherpetic neuralgia: treatment with amitriptyline is cheaper than with aciclovir. BMJ 2001; 322: 860–1PubMed
72.
Whitley R.J., Gnann Jr J.W., Hinthorn D., et al. Disseminated herpes zoster in the immunocompromised host: a comparative trial of acyclovir and vidarabine. J Infect Dis 1992; 165: 450–5PubMedCrossRef
73.
Meyers J.D. Treatment of the varicella zoster infections in immunocompromised patients. Res Clin Forums 1986; 9: 65–74
74.
Peterslund N.A. The treatment of herpes zoster infections. Scand J Infect Dis 1985; 17 Suppl. 47: 80–4
75.
Petterson E., Hovi T., Ahonen J., et al. Prophylactic oral aciclovir after renal transplantation. Transplantation 1985; 39: 279–81CrossRef
76.
Masaoka T., Hiraoka A., Teshima H., et al. Varicella zoster infection in immunocompromised patients. J Med Virol 1993; Suppl. 1: 82–4PubMedCrossRef
77.
Levin M.J., Zaia J.A., Hershey B.J., et al. Topical acyclovir treatment of herpes zoster in immunocompromised patients. J Am Acad Dermatol 1985; 13: 590–6PubMedCrossRef
78.
Rothe M.J., Feder Jr H.M., Grant-Kels J.M. Oral acyclovir therapy for varicella and zoster infections in pediatric and pregnant patients: a brief review. Pediatr Dermatol 1991; 8: 236–7PubMedCrossRef
79.
Sempere A., Sanz G.F., Senent L., et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992; 10: 495–8PubMed
80.
Ljungman P., Lonnquist B., Ringden O., et al. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Bone Marrow Transplant 1989; 4: 613–5PubMed
81.
Ladriere M., Bibes B., Rabaud C., et al. Varicella zoster virus infection after bone marrow transplant: unusual presentation and importance of prevention. Presse Med 2001; 30: 1151–4PubMed
82.
Yagi T., Karasuno T., Hasegawa T., et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir. Bone Marrow Transplant 2000; 25: 1003–5PubMedCrossRef
83.
Stemmer S.M., Kinsman K., Tellschow S., et al. Fatal noncutaneous visceral infection with varicella-zoster virus in a patient with autologous bone marrow tranplantation. Clin Inf Dis 1993; 16: 497–9CrossRef
84.
Novelli V.M., Marshall W.C., Yeo J., et al. Acyclovir administered perorally in immunocompromised children with varicella zoster infections. J Infect Dis 1984; 149: 478PubMedCrossRef
85.
Höglund M., Ljungman P., Weller S. Comparable aciclovir exposures produced by oral aciclovir in immunocompromised cancer patients. J Antimicrob Chemother 2001; 47: 855–61PubMedCrossRef
86.
Bomgaars L., Duran C., Khan S., et al. The pharmacokinetics of valaciclovir in immunocompromised children [abstract]. Clin Pharmcol Ther 2000; 69: PI58
87.
Levin M.J. Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol 2001; 146 Suppl. 17: 151–60
88.
Straus S.E. Varicella-zoster virus immunity and prevention: a conference perspective. Arch Virol 2001; 146 Suppl. 17: 173–8
89.
Takahashi M., Kamiya H., Asano Y., et al. Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction. Arch Virol 2001; 146 Suppl. 17: 161–72
90.
Gershon A.A. The current status of live attenuated varicella vaccine. Arch Virol 2001; 146 Suppl. 17: 1–6
Metadaten
Titel
Oral Antivirals Revisited in the Treatment of Herpes Zoster
What Do They Accomplish?
verfasst von
Dr Arjen F. Nikkels
Gérald E. Piérard
Publikationsdatum
01.12.2002
Verlag
Springer International Publishing
Erschienen in
American Journal of Clinical Dermatology / Ausgabe 9/2002
Print ISSN: 1175-0561
Elektronische ISSN: 1179-1888
DOI
https://doi.org/10.2165/00128071-200203090-00001

Weitere Artikel der Ausgabe 9/2002

American Journal of Clinical Dermatology 9/2002 Zur Ausgabe

Therapy in Practice

Causes and Management of Hypertrichosis

Pharmacovigilance

Cutaneous Drug Reaction Case Reports

Review Article

Adverse Cutaneous Reactions to Antipsychotics

Leading Article

NSAID-Induced Urticaria and Angioedema

Leading Article

Tumor Vaccines

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärztinnen und Psychotherapeuten.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise